Implication of prostaglandin receptors in the accumulation of osteoprotegerin in human osteoblast cultures

Journal of Rheumatology

Volumn 33, Issue 6, 2006, Pages 1167-1175

  Samadfam, Rana ^a,b   Gallant, Maxime A ^a,b   Miousse, Marie Claude ^a,b   Parent, Jean Luc ^a,b   De Brum Fernandes, Artur J ^a,b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b Division of Rheumatology   (Canada)

Author keywords

Cyclooxygenase; Osteoblast; Osteoprotegerin; Prostaglandin

Indexed keywords

11 DEOXYPROSTAGLANDIN E1; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; BUTAPROST; CALCIUM; CARBACYCLIN; CYCLIC AMP; DICLOFENAC; FLUPROSTENOL; G PROTEIN COUPLED RECEPTOR; INDOMETACIN; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; OSTEOPROTEGERIN; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN E2 DERIVATIVE; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SALICYLIC ACID DERIVATIVE; SULPROSTONE;

ARTICLE; BONE METABOLISM; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HUMAN; HUMAN CELL; OSTEOBLAST; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; HYDANTOINS; OSTEOBLASTS; OSTEOPROTEGERIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, PROSTAGLANDIN; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33744721062     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
2. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
3. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4.
4. Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
5. Yasuda H, Shima N, Nakagawa N, et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999;25:109-13.
6. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
7. Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-42.
8. Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998;273:5117-23.
9. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
10. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-5.
11. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-226.
12. Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994;269:19256-61.
13. Wright DH, Abran D, Bhattacharya M, et al. Prostanoid receptors: ontogeny and implications in vascular physiology. Am J Physiol Regul Integr Comp Physiol 2001;281:R1343-60.
14. An S, Yang J, So SW, Zeng L. Goetzl EJ. Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 1994;33:14496-502.
15. Irie A, Sugimoto Y, Namba T, et al. Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur J Biochem 1993;217:313-8.
16. Namba T, Sugimoto Y, Negishi M, et al. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 1993;365:166-70.
17. Klein DC, Raisz LG. Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 1970;86:1436-40.
18. Santoro MG, Jaffe BM, Simmons DJ. Bone resorption in vitro and in vivo in PGE-treated mice. Proc Soc Exp Biol Med 1977;156:373-7.
19. Fujieda M, Kiriu M, Mizuochi S, Hagiya K, Kaneki H, Ide H. Formation of mineralized bone nodules by rat calvarial osteoblasts decreases with donor age due to a reduction in signaling through EP(1) subtype of prostaglandin E(2) receptor. J Cell Biochem 1999;75:215-25.
20. Suda M, Tanaka K, Natsui K, et al. Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Endocrinology 1996;137:1698-705.
21. Suda M, Tanaka K, Sakuma Y, et al. Prostaglandin E(2) induces the c-fos and c-jun expressions via the EP(1) subtype of PGE receptor in mouse osteoblastic MC3T3-E1 cells. Calcif Tissue Int 2000;66:217-23.
22. Brandstrom H, Jonsson KB, Ohlsson C, Vidal O, Ljunghall S, Ljunggren O. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem Biophys Res Commun 1998;247:338-41.
23. Murakami T, Yamamoto M, Ono K, et al. Transforming growth factor-beta 1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 1998;252:747-52.
24. Wang X, Wu J, Shidoji Y, et al. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation. J Bone Miner Res 2002;17:91-100.
25. Sarrazin P, Bkaily G, Hache R, et al. Characterization of the prostaglandin receptors in human osteoblasts in culture. Prostaglandins Leukot Essent Fatty Acids 2001;64:203-10.
26. Chretien L, Richard DE, Poirier SN, Poitras M, Guillemette G. Bovine adrenal glomerulosa cells express such a low level of functional B2 receptors that bradykinin does not significantly increase their aldosterone production. J Endocrinol 1998;156:449-60.
27. de Brum-Fernandes AJ, Laporte S, Heroux M, et al. Expression of prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 in human osteoblasts. Biochem Biophys Res Commun 1994;198:955-60.
28. Maciel FM, Sarrazin P, Morisset S, et al. Induction of cyclooxygenase-2 by parathyroid hormone in human osteoblasts in culture. J Rheumatol 1997;24:2429-35.
29. O'Brien EA, Williams JH, Marshall MJ. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone 2001;28:208-14.
30. Brandstrom H, Bjorkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 2001;280:831-5.
31. Tomita M, Li X, Okada Y, et al. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone 2002;30:159-63.
32. Ono K, Akatsu T, Murakami T, et al. Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2. J Endocrinol 1998;158:R1-5.
33. Ohshiba T, Miyaura C, Ito A. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochem Biophys Res Commun 2003;300:957-64.
34. Li X, Pilbeam CC, Pan L, Breyer RM, Raisz LG. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone 2002;30:567-73.
35. Gallant MA, Samadfam R, Hackett JA, Antoniou J, Parent JL, de Brum-Fernandes AJ. Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. J Bone Miner Res 2005;20:672-81.
36. Halladay DL, Miles RR, Thirunavukkarasu K, Chandrasekhar S, Martin TJ, Onyia JE. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. J Cell Biochem 2001;84:1-11.
37. Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology Oxford 2002;41:1008-16.
38. Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623-30.
39. Matheson AJ, Figgitt DP. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 2001;61:833-65.
40. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:957-80.